You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The consortium, led by a Belgium biotech, will use the funds to advance an mRNA-based vaccine as a treatment for head and neck, cervical, and anogenital cancers.
The grant, awarded by the Eurostars program, will support the European companies in their goal of advancing their mRNA-based kidney cancer vaccine.
Based on the promising results, the company is advancing the tumor lysate, particle-loaded, dendritic cell vaccine into Phase III studies.
